Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kentaro Yamazaki

Showing results (221-230 of 252) with videos related to

Pageof 26
Sort By:
The New England Journal of Medicine|May 14, 2015
Randomized trial of TAS-102 for refractory metastatic colorectal cancerRobert J Mayer, Eric Van Cutsem, Alfredo Falcone, et al.
International Journal of Clinical Oncology|August 28, 2024
Real-world outcomes of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: the JSCCR-TRIPON studyYoshiyuki Yamamoto, Hiroki Yukami, Tatsuro Yamaguchi, et al.
JCO Precision Oncology|May 11, 2022
Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal CancerHideaki Bando, Yoshiaki Nakamura, Hiroya Taniguchi, et al.
Frontiers in Oncology|July 2, 2021
Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil TreatmentHiromichi Nakajima, Shota Fukuoka, Toshiki Masuishi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 25, 2026
Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)Yosuke Kito, Kentaro Yamazaki, Hirokazu Shoji, et al.
Frontiers in Oncology|March 25, 2021
Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS)Keigo Chida, Daisuke Kotani, Toshikazu Moriwaki, et al.
Annals of Surgery|September 26, 2025
Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery: A Prospective Cohort StudyKoji Ando, Atsushi Hamabe, Yoshiaki Nakamura, et al.
Chinese Journal of Cancer|December 24, 2016
Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumabMasahito Kotaka, Ruihua Xu, Kei Muro, et al.
Clinical Colorectal Cancer|August 29, 2018
Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal CancerKenji Tsuchihashi, Mamoru Ito, Toshikazu Moriwaki, et al.
British Journal of Cancer|August 2, 2023
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)Koji Ando, Yoshiaki Nakamura, Hiroyuki Kitao, et al.
Pageof 26

Showing results (221-230 of 252) with videos related to

Sort By:
Pageof 26
The New England Journal of Medicine|May 14, 2015
Randomized trial of TAS-102 for refractory metastatic colorectal cancerRobert J Mayer, Eric Van Cutsem, Alfredo Falcone, et al.
International Journal of Clinical Oncology|August 28, 2024
Real-world outcomes of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: the JSCCR-TRIPON studyYoshiyuki Yamamoto, Hiroki Yukami, Tatsuro Yamaguchi, et al.
JCO Precision Oncology|May 11, 2022
Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal CancerHideaki Bando, Yoshiaki Nakamura, Hiroya Taniguchi, et al.
Frontiers in Oncology|July 2, 2021
Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil TreatmentHiromichi Nakajima, Shota Fukuoka, Toshiki Masuishi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 25, 2026
Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)Yosuke Kito, Kentaro Yamazaki, Hirokazu Shoji, et al.
Frontiers in Oncology|March 25, 2021
Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS)Keigo Chida, Daisuke Kotani, Toshikazu Moriwaki, et al.
Annals of Surgery|September 26, 2025
Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery: A Prospective Cohort StudyKoji Ando, Atsushi Hamabe, Yoshiaki Nakamura, et al.
Chinese Journal of Cancer|December 24, 2016
Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumabMasahito Kotaka, Ruihua Xu, Kei Muro, et al.
Clinical Colorectal Cancer|August 29, 2018
Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal CancerKenji Tsuchihashi, Mamoru Ito, Toshikazu Moriwaki, et al.
British Journal of Cancer|August 2, 2023
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)Koji Ando, Yoshiaki Nakamura, Hiroyuki Kitao, et al.
Pageof 26